Abstract:Согласно рекомендациям Международной рабочей группы по изучению спондилоартритов (ASAS), ингибиторы фактора некроза опухоли α (иФНОα) рекомендуется назначать больным анкилозирующим спондилитом (АС), рефрактерным как минимум к двум нестероидным противовоспалительным препаратам (НПВП), и пациентам с периферической формой заболевания. Результаты ранее проведенных исследований свидетельствуют о стойкой эффективности инфликсимаба (ИНФ) при длительной терапии у преобладающего большинства больных активным АС. Работ, … Show more
6 clinical cases of ankylosing spondylitis in male patients of average working age were considered. Patients had non-axial and extra-skeletal manifestations of ankylosing spondylitis, varying disease duration and adherence to therapy. The effectiveness of the use of two groups of genetically engineered biological drugs has been analyzed and evaluated.
6 clinical cases of ankylosing spondylitis in male patients of average working age were considered. Patients had non-axial and extra-skeletal manifestations of ankylosing spondylitis, varying disease duration and adherence to therapy. The effectiveness of the use of two groups of genetically engineered biological drugs has been analyzed and evaluated.
Introduction. Ankylosing spondylitis and Crohn's disease are chronic recurrent autoimmune diseases. In case of a combined course their activity tends to progress, regardless of the phase of the underlying disease.The aim of the study. To analyze the combination of ankylosing spondylitis and Crohn's disease, issues of its diagnosis and selection of therapy.Results. The combination of ankylosing spondylitis and Crohn's disease tend to progress independently, regardless of the phase of the underlying disease. The main problem that complicates diagnosis is the lack of a unifed approach to the defnition of extra skeletal and extraintestinal manifestations.Conclusion. The management of patients with a combination of ankylosing spondylitis and Crohn's disease is a common problem of rheumatologists and gastroenterologists. An interdisciplinary approach will allow timely diagnosis of extra-skeletal and extra-intestinal manifestations and correct therapy.
The article presents a review of studies that have examined osteoporosis in rheumatic diseases, including rheumatoid arthritis, spondylarthritis, psoriatic arthritis, systemic connective tissue diseases, and systemic vasculitis. The review discusses the pathogenesis, diagnosis and treatment of osteoporosis in these diseases, presents the results of epidemiological studies assessing the risk factors and the prevalence of osteoporosis in rheumatic diseases. There was a high prevalence of osteoporosis and fractures in rheumatic diseases, exceeding the population, associated primarily with systemic and local inflammation, as well as with the intake of glucocorticoids. It is indicated that the existing strategies for the treatment of rheumatic diseases may partially reduce bone loss, but long-term administration of glucocorticoids, on the contrary, increase bone resorption. The review presents data on the medications for the treatment of osteoporosis and approaches to the treatment of glucocorticoid osteoporosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.